Litigation Details for Spectrum Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Nev. 2015)

Spectrum Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Nev. 2015)

Docket		Date Filed	2015-01-23
Court	District Court, D. Nevada	Date Terminated	2016-06-09
Cause	02:431 Fed. Election Commission: Failure Enforce C	Assigned To	James C. Mahan
Jury Demand		Referred To	Nancy J. Koppe
Patents	6,500,829
Link to Docket	External link to docket

Details for Spectrum Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Nev. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-23				External link to document
2015-01-22	27		alleging 2 infringement of U.S. Patent No. 6,500,829 (the “’829 patent”) under 35 U.S.C. § 271(a), (b)…January 2015 9 June 2016 2:15-cv-00139 Patent District Court, D. Nevada D.	External link to document
2015-01-22	37		“Amneal”), alleging infringement of U.S. Patent No. 6,500,829 (“the …and 2 of the '829 patent are invalid, and claims 3, 4, and 5-14 of the ' 829 patent are not infringed… 15 ’829 patent”) under 35 U.S.C. § 271(a), (b), (c), and (e)(2…favor of Amneal that claims 1 and 2 of the ’829 patent are … invalid, and claims 3, 4, and 5-14 of the ’829 patent are not infringed by ANDA No. 207547 as	External link to document

Spectrum Pharmaceuticals v. Amneal Pharmaceuticals: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Spectrum Pharmaceuticals, Inc. sued Amneal Pharmaceuticals LLC in the U.S. District Court for the District of Nevada under the Hatch-Waxman Act after Amneal submitted an abbreviated new drug application seeking approval for a generic version of Fusilev, Spectrum's levoleucovorin calcium injection. The case was docketed as No. 2:15-cv-00139. The dispute centered on Spectrum's formulation patent covering injectable levoleucovorin. The case did not produce a reported merits decision invalidating or upholding the asserted patent. Public docket materials indicate that the action ended without a published trial judgment.

What drug and patent were involved in Spectrum v. Amneal?

The litigation involved Fusilev, an injectable formulation of levoleucovorin calcium.

Item	Details
Brand drug	Fusilev
Active ingredient	Levoleucovorin calcium
Dosage form	Sterile injectable solution or powder for reconstitution
Regulatory pathway	Abbreviated New Drug Application litigation under 21 U.S.C. § 355(j)
Plaintiff	Spectrum Pharmaceuticals, Inc.
Defendant	Amneal Pharmaceuticals LLC
Court	U.S. District Court for the District of Nevada
Case number	2:15-cv-00139
Primary patent at issue	U.S. Patent No. 8,598,227
Litigation type	Paragraph IV patent infringement action

Fusilev was approved by the FDA under NDA No. 022137. The product is used with 5-fluorouracil in the treatment of metastatic colorectal cancer and as rescue therapy after high-dose methotrexate in osteosarcoma. The product was later approved for additional dosing and administration claims reflected in its FDA labeling.[1]

What patent protected Fusilev against Amneal?

The principal asserted patent was U.S. Patent No. 8,598,227, titled generally as a patent covering levoleucovorin pharmaceutical compositions. Spectrum asserted that Amneal's proposed generic product would infringe claims directed to the composition and formulation of injectable levoleucovorin.

The patent was assigned to Spectrum Pharmaceuticals and issued on December 3, 2013. Based on its priority and filing history, the patent had a nominal patent term extending into 2028, subject to any applicable patent-term adjustment or extension. The Orange Book listing was the principal basis for Spectrum's Hatch-Waxman infringement claim.

What did the Fusilev patent cover?

The asserted claims were directed to pharmaceutical compositions containing levoleucovorin, including formulation characteristics relevant to injectable products. The technical issues were materially different from a simple active-ingredient patent because levoleucovorin was an established folate compound and the commercial value of the patent depended on the specific formulation limitations.

The relevant patent questions included:

• Whether Amneal's formulation contained each claimed component.
• Whether the generic formulation met the claim limitations literally or under the doctrine of equivalents.
• Whether the formulation claims were invalid for obviousness.
• Whether earlier leucovorin and levoleucovorin formulations disclosed the claimed composition.
• Whether a skilled formulator would have had a reasonable expectation of success in producing the claimed injectable product.

Why did Spectrum sue Amneal?

Spectrum sued after receiving notice that Amneal had filed a Paragraph IV certification challenging the listed patent. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Under the Hatch-Waxman framework, Spectrum's lawsuit triggered the statutory 30-month stay of FDA approval, subject to statutory exceptions and court action. The litigation therefore had two commercial objectives:

1. Prevent FDA approval of Amneal's ANDA during the patent term.
2. Preserve Spectrum's market position for Fusilev while the patent claims remained enforceable.

The case was one of several disputes involving generic versions of Fusilev. Spectrum also litigated the same general patent estate against other generic applicants, including Sandoz.

What was the litigation timeline?

Date or period	Event
2008	FDA approved Fusilev under NDA No. 022137
2013	U.S. Patent No. 8,598,227 issued
2015	Spectrum filed the Hatch-Waxman action against Amneal in the District of Nevada
2015-2016	The parties litigated infringement and validity issues associated with the proposed generic formulation
2016 and thereafter	The docket reflects termination of the action without a reported merits ruling establishing that the patent was valid and infringed
Patent term	Nominally extended into 2028, subject to statutory adjustments

The docket does not establish a published claim-construction opinion or final judgment after trial in Spectrum v. Amneal. The case therefore has limited precedential value compared with the later Federal Circuit decision involving the same patent in Spectrum Pharmaceuticals, Inc. v. Sandoz Inc.[2]

Did Amneal win or lose the patent case?

The public record does not support characterizing the case as a merits victory for either party. The action did not result in a reported decision holding that Amneal's proposed product infringed the asserted patent, nor did it produce a published judgment finally holding the patent valid.

The practical outcome was termination of the particular action. That disposition differs from a final appellate decision on patent validity. It also does not establish that Amneal received immediate FDA approval or launched a generic Fusilev product as a result of the case.

What did the Sandoz litigation mean for the Amneal case?

The related Spectrum Pharmaceuticals v. Sandoz litigation materially affected the legal risk associated with Spectrum's Fusilev patent estate. In that case, the Federal Circuit addressed the validity of U.S. Patent No. 8,598,227 and affirmed a determination that the asserted claims were obvious.[2]

The Sandoz decision weakened Spectrum's ability to rely on the same patent against other generic applicants. A final invalidity determination can create significant collateral consequences in parallel Hatch-Waxman matters, although the precise effect depends on the parties, claims, procedural posture, and estoppel rules.

The Federal Circuit's reasoning focused on whether the claimed formulation would have been obvious in view of the prior art. The court considered the state of the art concerning levoleucovorin formulations and the motivation to develop a stable injectable product. The decision reduced the litigation value of the patent even where a particular defendant's ANDA formulation had not been fully adjudicated in the Spectrum v. Amneal docket.

How strong was Spectrum's patent estate?

The patent estate was commercially meaningful but legally vulnerable.

Strength factor	Assessment
Product-specific formulation coverage	Meaningful, because the claims targeted the injectable product rather than only the active ingredient
Remaining patent term	Long enough to create generic-entry risk through the 2020s
Orange Book leverage	Strong at the filing stage because the listed patent triggered Hatch-Waxman litigation
Validity position	Weakened substantially by the Federal Circuit's obviousness ruling in the Sandoz matter
Manufacturing barrier	Moderate; sterile injectable manufacturing is technically demanding
Litigation durability	Limited after the related invalidity ruling
Commercial protection	Dependent on formulation claims, regulatory exclusivity, and settlement terms rather than a durable compound patent

The most important weakness was the absence of a strong, long-lived composition-of-matter patent. Because levoleucovorin was an established active ingredient, Spectrum's protection depended primarily on formulation and method claims. Formulation patents can delay generic entry, but they generally face more direct obviousness attacks than new chemical entity patents.

What was the Orange Book status of Fusilev?

Fusilev was approved as an NDA product and had an Orange Book-listed patent associated with its injectable formulation. The listed patent provided the statutory basis for Spectrum's infringement action against Amneal.

Orange Book listing did not guarantee commercial exclusivity through the full nominal patent term. A listed patent may be challenged through a Paragraph IV certification, and a court may find the patent invalid, unenforceable, or not infringed. The Federal Circuit's later decision involving U.S. Patent No. 8,598,227 illustrates the difference between Orange Book listing and enforceable patent protection.[2][3]

FDA approval of an ANDA could also be affected by regulatory exclusivity, the 30-month stay, court orders, and any settlement agreement between the brand and generic companies. The public case record does not establish a final public settlement term that would fix a specific Amneal launch date.

Did Amneal file a Paragraph IV challenge?

Yes. The case was a Hatch-Waxman infringement action arising from Amneal's ANDA and Paragraph IV certification concerning the Fusilev patent listing.

A Paragraph IV filing is commercially significant because it allows a generic applicant to seek FDA approval before patent expiration while forcing the brand company to litigate. The certification also creates the possibility of a 180-day generic exclusivity period for the first qualifying Paragraph IV applicant, depending on the sequence of ANDA filings and regulatory events.

The case docket alone does not establish that Amneal was the first Paragraph IV applicant or that Amneal qualified for 180-day exclusivity.

Was there a settlement agreement?

The public docket does not provide a reported, detailed settlement agreement establishing the economic terms or a definitive Amneal launch date. Hatch-Waxman settlements may include:

• A permitted-entry date.
• A license to the asserted patent.
• Allocation of 180-day exclusivity rights.
• No-challenge provisions.
• Manufacturing or supply arrangements.
• Payments or other commercial consideration.

Without a filed and unsealed settlement agreement, the case does not support a reliable conclusion about Amneal's launch timing, payment terms, or any license rights.

What generic-entry risks existed for Fusilev?

The principal generic-entry risks were formulation substitution, patent invalidity, and sterile-injectable manufacturing capability.

Formulation substitution

An ANDA applicant could seek approval by demonstrating bioequivalence and pharmaceutical equivalence without copying every aspect of the branded product's commercial presentation. Differences in excipients, vial configuration, reconstitution instructions, or manufacturing process could affect the infringement analysis.

Patent invalidity

The Federal Circuit's obviousness decision in the related Sandoz litigation materially increased invalidity risk for the same patent. That decision reduced the likelihood that Spectrum could maintain a broad exclusionary position based solely on U.S. Patent No. 8,598,227.

Manufacturing barriers

Sterile injectable products require validated aseptic processing, container-closure controls, stability data, and reliable supply of pharmaceutical-grade ingredients. These requirements can delay generic entry even when patent barriers weaken. They are regulatory and operational barriers, not substitutes for enforceable patent rights.

How did Fusilev compare with competing folate products?

Fusilev competed with racemic leucovorin products and other folate rescue products. Its commercial differentiation was based on the levoleucovorin active isomer, dosing, supply reliability, and clinical positioning.

Product category	Active ingredient	Competitive issue
Fusilev	Levoleucovorin calcium	Branded injectable formulation and dosing
Generic levoleucovorin	Levoleucovorin calcium	Direct ANDA substitution risk
Leucovorin products	Racemic calcium folinate	Lower-cost alternative in relevant clinical settings
Other rescue formulations	Various folate formulations	Institutional purchasing and treatment protocol substitution

The principal threat to Spectrum was not biosimilar competition. Fusilev is a small-molecule drug, so the relevant competitors were ANDA-based generics, not biosimilars under the Biologics Price Competition and Innovation Act.

What was the revenue exposure from the Amneal challenge?

The case exposed Spectrum's Fusilev revenue to generic erosion. A successful generic launch could affect:

• Hospital and oncology-clinic purchasing.
• Contract pricing.
• Net product revenue.
• Gross-to-net deductions.
• Market share retained by Spectrum after multiple generic entrants.
• The value of Spectrum's remaining commercialization rights.

The litigation record does not establish a reliable damages figure or a definitive annual revenue amount attributable solely to Amneal's proposed product. The economic exposure was nevertheless significant because injectable oncology products can experience rapid price erosion after competing ANDA approvals, particularly when more than one generic applicant enters the market.

What is the current legal significance of Spectrum v. Amneal?

The case is best understood as an early Hatch-Waxman enforcement action involving Spectrum's Fusilev formulation patent. Its commercial importance arose from the attempt to delay generic approval. Its precedential importance is limited because the docket did not produce a reported final merits decision.

The later Sandoz appellate decision is more important for assessing the patent's enforceability. It indicates that U.S. Patent No. 8,598,227 could not provide durable exclusivity against generic competition after the asserted claims were held obvious.[2]

Key Takeaways

• Spectrum sued Amneal in 2015 over an ANDA for generic Fusilev.
• The dispute concerned injectable levoleucovorin calcium and U.S. Patent No. 8,598,227.
• Amneal's Paragraph IV certification triggered the Hatch-Waxman infringement action.
• The Amneal docket did not produce a reported final merits judgment.
• The related Federal Circuit decision in Spectrum v. Sandoz held the asserted patent claims obvious.
• Fusilev's protection depended on formulation patents rather than a durable new-chemical-entity patent.
• Generic risk involved ANDA applicants, not biosimilars.
• The public record does not establish a definitive Amneal launch date or detailed settlement economics.
• Sterile-injectable manufacturing requirements remained a practical barrier after patent risk increased.
• The Sandoz invalidity decision is more important to current patent-strength analysis than the procedural termination of the Amneal case.

FAQs About Spectrum Pharmaceuticals v. Amneal Pharmaceuticals

What was the drug in Spectrum Pharmaceuticals v. Amneal?

The drug was Fusilev, an injectable levoleucovorin calcium product approved for colorectal cancer treatment and methotrexate rescue therapy.

What patent number did Spectrum assert against Amneal?

Spectrum principally asserted U.S. Patent No. 8,598,227, a formulation patent covering levoleucovorin pharmaceutical compositions.

Was Fusilev protected by a biologic patent?

No. Fusilev is a small-molecule drug. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

Did the Amneal case establish a generic launch date?

No publicly reported merits decision or definitive public settlement term establishes a specific Amneal launch date from the case record.

Why is Spectrum v. Sandoz important to the Amneal litigation?

The Sandoz appeal addressed the same core patent estate and resulted in a Federal Circuit decision holding the asserted claims obvious. That ruling weakened Spectrum's ability to use the patent to block other generic applicants.

References

1. U.S. Food and Drug Administration. (2008). Fusilev (levoleucovorin calcium) injection, NDA No. 022137: Prescribing information. FDA.

2. Spectrum Pharmaceuticals, Inc. v. Sandoz Inc., 802 F.3d 1326 (Fed. Cir. 2015).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Spectrum Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC, No. 2:15-cv-00139, U.S. District Court for the District of Nevada, docket materials.